Arcturus Therapeutics (NASDAQ:ARCT) Announces Quarterly Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) issued its earnings results on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21, Yahoo Finance reports. The business had revenue of $49.86 million during the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. During the same quarter in the prior year, the firm earned ($1.98) earnings per share.

Arcturus Therapeutics Trading Down 5.5 %

Shares of NASDAQ:ARCT traded down $1.10 during trading on Wednesday, reaching $18.73. 618,306 shares of the company traded hands, compared to its average volume of 516,145. The firm has a market capitalization of $504.44 million, a price-to-earnings ratio of -5.07 and a beta of 2.64. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $45.00. The business’s fifty day moving average is $26.93 and its 200-day moving average is $30.92.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ARCT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Tuesday. Canaccord Genuity Group cut their target price on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research note on Friday, May 10th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $67.60.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 26,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $40.01, for a total value of $1,040,260.00. Following the completion of the sale, the chief operating officer now owns 447,448 shares of the company’s stock, valued at $17,902,394.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.80% of the stock is currently owned by insiders.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.